Loading…
Albemarle
NYSE: ALB Materials Chemicals 🔎 Screen
S&P 500
$16.9B
Market Cap
10.8
P/E
7.66
PEG
-7.0%
ROCE
-8.6%
ROE
0.32
D/E
-7.1%
OPM
-34.2%
% from 52W High
80
α RS
🔍 ALB is showing a sector-leadership setup because Sector RRG has Materials in the Leading quadrant with the trail still strengthening, it matches 2 of 37 tracked screener presets, and RS Rating is 80. Net: Broad signal stack, not a recommendation. ? RRG Conviction RS Rating
Sources
Materials in Leading quadrant · Conviction 2/37 · RS Rating 80
⚖️ Compare 🔒 Generate Report 🔒 Research Packet 📚 Guides
🌏 Global Investor Returns
Currency-adjusted total returns for ALB including FX impact
🌏
Click 🌏 Returns tab to load data
📈 Price History
Ratio Health
Excellent
Good
Average
Poor
By Category
📊 Sector Averages
About

Albemarle Corporation provides energy storage solutions worldwide.

Key Ratios Snapshot
📈 Growth Pattern
📊 Quick Scorecard
Loading…
⭐ Superinvestors Holding ALB
View All Superinvestors →
Manager Shares Value % of Fund Period
Jim Simons Renaissance Technologies LLC 730.7K $131.2M 0.21% Mar 2026

SEC Form 13F data. 45-day lag from quarter end.

🔒
Premium Feature
AI-generated 10-section company profile — business model, financials, strengths, risks & management quality
Upgrade to Premium
Already a member? Log in
📐
3-Statement Financial Model
Bear / Base / Bull projections · DCF fair value · Reverse-DCF
Open Model →
🎙 Management Tone Confident Specific → Stable 5 quarters Full tone analysis in Intelligence →
Good quarter Investor Presentation One-Pager? Q2 2026
Revenue
$1.7B
+31% YoY
Adjusted EBITDA
$858M
+155% YoY
Net Income
$480M
+1,996% YoY
What Went Right
  • Adjusted EBITDA surged 155% to $858M, with the enterprise EBITDA margin expanding to 49%.
  • Cash from operations was $710M and free cash flow $638M, an 83% operating cash conversion.
  • Specialties delivered net sales of $424M (+20% YoY) and adjusted EBITDA of $118M (+61% YoY) on pricing, volumes and mix.
What to Watch
  • Q3 energy storage sales, EBITDA and margins are expected to decline sequentially due to lower volumes and current pricing assumptions.
  • The Greenbushes CGP3 fire delayed full run-rate to Q1 2027, trimming energy storage full-year sales volume to 225-235kT LCE.
  • Middle East supply chain disruptions are still estimated at $70-90M of unmitigated full-year EBITDA impact, with specialty prices normalizing after an April peak.
Management Guidance
  • Total company outlook ranges maintained and expected to land at the high end of scenario ranges.
  • Specialties full-year net sales outlook raised to $1.4-1.6B and adjusted EBITDA to $275-325M.
  • Energy storage full-year sales volume guided to 225-235kT LCE, flat to down 4% YoY.
  • Full-year capital expenditure reduced to approximately $500M on capital efficiency improvements.
Investor Lens
The investment thesis is stronger after this quarter. Deliveries are accelerating — revenue grew 31% to $1.7B, adjusted EBITDA more than doubled to $858M, and specialties guidance was raised while capex was cut. Lithium demand remains well above expectations, with spot inventories near historic lows, and Wodgina outperformance is offsetting much of the CGP3 disruption. The main offsets are sequential Q3 softness, a still-uncertain Middle East cost drag and delayed CGP3 full ramp, but the underlying demand and cash generation narrative is intact.
From investor presentation · AI-generated analysis · Not investment advice
🔒
Premium Feature
Investor Presentation One-Pager — quarterly highlights, what went right/wrong & management guidance
Upgrade to Premium
Already a member? Log in
📈 STRONG Q2 2026 beat with revenue +31% and adjusted EBITDA +155%.
Revenue
Net sales rose 31% YoY to $1.7B. Energy storage grew 78% on +73% pricing, while specialties grew 20% on +11% price and +8% volume.
Profitability
Net income attributable to Albemarle was $480M versus $22.9M a year ago, with diluted EPS of $3.52. Adjusted EBITDA more than doubled to $858M, up 155% YoY.
Margins
Enterprise adjusted EBITDA margin expanded to 49%. Energy storage adjusted EBITDA jumped 229%, while specialties margin rose 700bps to 28%.
Balance Sheet
Cash from operations was $710M and free cash flow $638M. Full-year capex was lowered to approximately $500M, though full-year cash flow is still impacted by $87.5M of deferred revenue and ~$100M of Kemerton idling spend.
Key Risks
Management guided Q3 net sales and EBITDA lower sequentially, with energy storage margins pressured by spodumene timing. The CGP3 fire delays full run-rate to Q1 2027, and Middle East-related supply chain costs remain a $70-90M unmitigated full-year risk.
Outlook
Total company outlook remains at the high end of scenario ranges, with specialties raised to $1.4-1.6B sales and $275-325M adjusted EBITDA. Energy storage volumes are expected at 225-235kT LCE for the full year.
Generated by AI · Q2 2026 results · Not investment advice
🔒
Free Account Required

Create a free Finmagine account to access Finmagine™ Scorecard.

See how this company scores across 5 dimensions — Financial Health, Growth Prospects, Competitive Position, Management Quality, and Valuation — powered by 30+ computed ratios.

Create Free AccountLog In
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Ask AI.

Get 25 expert AI analysis templates — Business KPIs, Comprehensive, Forensic Governance, Peer Comparison, Risk-Reward, Full Research Report, IPO Decoder, Red Flag Detector, and more — ready to paste into ChatGPT, Claude, Gemini, or Perplexity.

Upgrade to PremiumCreate Free Account
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Peer Comparison.

Compare this company side-by-side against its sector peers with financial metrics, ratio benchmarking, and relative performance across all key dimensions.

Upgrade to PremiumCreate Free Account
✓ 📞 Earnings Call Transcripts (5 quarters) submit a missing quarter
🔍
🔎 See cross-company document search → ?
📞 Earnings Call Transcripts (5)
Q2 2026 Q2 2026 2026-08-06
Q2 2026 saw net sales rise 31% year-over-year to $1.7 billion, with adjusted EBITDA more than doubling and strong cash generation. The outlook was raised for specialties, while energy storage volumes are expected to be flat to slightly down due to a plant fire, offset by JV outperformance.
Q1 2026 Q1 2026 2026-05-07
Q1 2026 saw net sales rise 33% and adjusted EBITDA more than double, driven by strong lithium and specialties demand, higher pricing, and operational improvements. Debt repayment and productivity gains strengthened the balance sheet, while guidance for specialties was raised amid resilient end markets.
Q4 2025 Q4 2025 2026-02-12
Q4 2025 saw 16% sales growth and 7% higher adjusted EBITDA, driven by energy storage and cost improvements. 2026 guidance anticipates margin gains, stable capital spending, and positive free cash flow if lithium prices hold. Asset sales and cost actions enhance financial flexibility.
Q3 2025 Q3 2025 2025-11-06
Q3 2025 saw record lithium production, a 7% rise in Adjusted EBITDA, and strong cash flow, with full-year results expected at the upper end of guidance. Asset sales and cost improvements enhance financial flexibility, while robust EV and grid storage demand drive growth.
Q2 2025 Q2 2025 2025-07-31
Q2 results showed lower sales and EBITDA year-over-year due to weak lithium pricing, but cost savings and productivity gains offset some impact. CapEx was cut by 60% and positive free cash flow is now expected for 2025. Strong liquidity and disciplined capital allocation support long-term growth.
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Catalyst Timeline.

Every result, order win, insider trade, ECS update, earnings-call, and SEC announcement for this company — in one chronological lane.

Upgrade to PremiumCreate Free Account
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Full Report.

Read the complete Finmagine™ investment research report — comprehensive fundamental analysis, business model assessment, competitive positioning, and investment recommendation.

Upgrade to PremiumCreate Free Account

📊 Analysis Methodology

This comprehensive investment analysis was conducted using The Finmagine™ Stock Analysis & Ranking Methodology, a proprietary framework that systematically evaluates stocks across five critical dimensions: Financial Health, Growth Prospects, Competitive Positioning, Management Quality, and Valuation.

🎯
Discover Our Proven Investment Framework Learn how we analyze and rank stocks using advanced quantitative models, multi-dimensional scoring systems, and dynamic discriminatory ranking techniques that have guided successful investment decisions across market cycles.
📊 Explore The Finmagine™ Methodology

A comprehensive, bias-free framework for analyzing and ranking stocks by Financial Strength, Growth Potential, Competitive Edge, Management Quality, and Value.

Financial Model
Projections are built from each company's audited annual financials (Income Statement, Balance Sheet, Cash Flow) over the last 5 fiscal years. Forward assumptions — revenue growth %, EBITDA margin, D&A (USD millions), interest expense, tax rate, and capex — are AI-generated using historical context and refreshed twice a year: after the December results season and after the September/Q4 results season.

DCF Valuation
Fair Value = Σ(FCFt / (1+WACC)t) + Terminal Value. Terminal Value uses the Gordon Growth Model: FCF5 × (1+g) / (WACC−g). Default WACC: 10% (US risk-free ~4.5%, equity risk premium ~5.5%). Default terminal growth: 3% (long-run US nominal GDP proxy).

CAGR Tracker
Expected 5-year CAGR = (DCF Fair Value / Current Price)1/5 − 1. Assumes fair value is reached in exactly 5 years — a mechanical estimate only.

Data Sources & Limitations
Financial statements sourced from public filings. Prices updated daily. Forward assumptions are AI-generated. All monetary values in USD millions. Non-US ADR companies may have currency conversion inaccuracies. Models are point-in-time and do not update intra-quarter or account for M&A, macro shocks, or extraordinary items.

⚠️ Important Disclaimers — Please read without fail.

Investment Risk:
Investing in securities, including US equities and ETFs, involves inherent risks including the potential loss of principal. All investments are subject to market fluctuations, economic conditions, regulatory changes, and other factors that may affect their value. Past performance is not indicative of future results. This analysis is provided for informational and educational purposes only and should not be construed as investment advice under any circumstances.

No Investment Recommendation:
This analysis does not constitute, nor should it be interpreted as, an offer, solicitation, or recommendation to buy, sell, or hold any securities or financial products. Investors are strongly advised to conduct their own independent research and due diligence and to consult with a licensed financial advisor or an SEC-registered investment adviser before making any investment decisions, taking into account their individual financial situation, risk tolerance, and investment objectives.

Not SEC-Registered:
Finmagine is not registered as an investment adviser with the U.S. Securities and Exchange Commission (SEC) or any state securities authority. Nothing on this platform constitutes investment advice as defined under the Investment Advisers Act of 1940.

Conflict of Interest Disclosure:
The author and/or analyst may currently hold or have previously held positions in the securities discussed. Any such positions are not intended to influence the objectivity or independence of the analysis. This research is produced independently and is not sponsored, endorsed, or commissioned by any company or institution.

Information Sources:
The analysis is based on publicly available information including SEC filings (10-K, 10-Q), annual reports, management commentary, and publicly available financial data. Information is believed to be accurate as of the date of publication but may be subject to change without notice. Readers are encouraged to independently verify all information before acting upon it.

Forward-Looking Statements:
This analysis may contain forward-looking statements, forecasts, or projections that are inherently subject to risks, uncertainties, and assumptions. Actual results may differ materially from those expressed or implied. Finmagine does not undertake any obligation to update such statements in the future.

Limitation of Liability:
The content is provided "as is" without any warranties, express or implied. Finmagine expressly disclaims any liability for errors, omissions, or any losses incurred as a result of reliance on the information provided. Readers assume full responsibility for their investment decisions.